PharmaTher Seeking Trial of Ketamine for Levodopa-Induced Dyskinesia

PharmaTher Seeking Trial of Ketamine for Levodopa-Induced Dyskinesia

292676

PharmaTher Seeking Trial of Ketamine for Levodopa-Induced Dyskinesia

PharmaTher is seeking regulatory approval to launch a clinical trial of the painkiller ketamine for levodopa-induced dyskinesia — the uncontrolled, involuntary movements that affect as many as 80% of Parkinson’s patients following treatment. The company, which focuses on the research and development of psychedelic pharmaceuticals, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a study of low-dose ketamine, an anesthetic available by prescription in the U.S. The…

You must be logged in to read/download the full post.